2 results
Approved WMORecruitment stopped
PrimaryPhase 1-To characterize the safety and tolerability of isatuximab in combination with cemiplimab in participants with relapsed and refractory cHL, DLBCL or PTCL, and to confirm the recommended Phase 2 dose (RP2D).Phase 2- Cohort A1 (anti-…
Approved WMORecruiting
To study the interaction between normal T lymphocytes and Hodgkin tumor cells in an in vitro model.